Vistagen Files 8-K on Dec 27 Event; Details Pending
Ticker: VTGN · Form: 8-K · Filed: Jan 3, 2024 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Jan 3, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-event, 8-K, regulatory-filing
TL;DR
**Vistagen filed an 8-K for a Dec 27 event, details to follow, watch for impact.**
AI Summary
Vistagen Therapeutics, Inc. filed an 8-K on January 3, 2024, reporting an event that occurred on December 27, 2023. This filing, under 'Other Events' and 'Financial Statements and Exhibits,' updates the public on a significant, though unspecified, corporate development. For investors, this matters because 8-K filings often signal material changes that could impact the company's stock price, making it crucial to understand the underlying event once more details are released.
Why It Matters
This 8-K signals a potentially significant, but currently undisclosed, corporate event for Vistagen Therapeutics, Inc., which could influence investor sentiment and stock valuation.
Risk Assessment
Risk Level: medium — The risk is medium because the filing indicates an 'Other Event' without specific details, creating uncertainty about its nature and potential impact on the company.
Analyst Insight
A smart investor would monitor Vistagen Therapeutics, Inc. for follow-up filings or press releases that detail the 'Other Event' from December 27, 2023, before making any investment decisions, as the current filing lacks specific actionable information.
Key Numbers
- December 27, 2023 — Date of earliest event reported (This is the date of the event that triggered the 8-K filing.)
- January 3, 2024 — Filing date of the 8-K (This is when the 8-K was officially filed with the SEC.)
- 000-54014 — Commission File Number (Unique identifier for Vistagen Therapeutics, Inc. with the SEC.)
- 20-5093315 — IRS Employer Identification Number (Tax identification number for Vistagen Therapeutics, Inc.)
- $0.001 — Par value per share of Common Stock (The nominal value assigned to each share of Vistagen's common stock.)
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — the registrant filing the 8-K
- Nevada (company) — state of incorporation for Vistagen Therapeutics, Inc.
- Nasdaq Capital Market (company) — exchange where Vistagen's Common Stock is registered
- 001-37761 (dollar_amount) — SEC File Number for Vistagen Therapeutics, Inc.
- 343 Allerton Ave. South San Francisco , California 94090 (company) — principal executive offices of Vistagen Therapeutics, Inc.
Forward-Looking Statements
- Vistagen Therapeutics, Inc. will file an amendment or a subsequent 8-K providing specific details about the 'Other Event' reported on December 27, 2023. (Vistagen Therapeutics, Inc.) — high confidence, target: Q1 2024
FAQ
What was the specific 'Other Event' that Vistagen Therapeutics, Inc. reported on December 27, 2023?
The filing does not specify the nature of the 'Other Event' that occurred on December 27, 2023. It only indicates that an event under Item 8.01, 'Other Events,' was reported.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 3, 2024, as indicated by the 'FILED AS OF DATE' and 'DATE AS OF CHANGE' in the filing header.
What is the trading symbol and exchange for Vistagen Therapeutics, Inc.'s Common Stock?
Vistagen Therapeutics, Inc.'s Common Stock trades under the symbol VTGN on the Nasdaq Capital Market, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section.
What is the business address of Vistagen Therapeutics, Inc.?
The business address of Vistagen Therapeutics, Inc. is 343 Allerton Ave., South San Francisco, California 94090, as listed in the filing.
Is Vistagen Therapeutics, Inc. considered an emerging growth company?
The filing includes a checkbox 'Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933,' but the box is not checked, implying it is not currently identifying as an emerging growth company for the purpose of this filing.
Filing Stats: 532 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-01-03 17:09:52
Key Financial Figures
- $0.001 — ch registered Common Stock , par value $0.001 per share VTGN Nasdaq Capital Market
Filing Documents
- vtgn20240103_8k.htm (8-K) — 22KB
- ex_611644.htm (EX-99.1) — 19KB
- a01.jpg (GRAPHIC) — 2KB
- 0001437749-24-000419.txt ( ) — 181KB
- vtgn-20231227.xsd (EX-101.SCH) — 3KB
- vtgn-20231227_def.xml (EX-101.DEF) — 11KB
- vtgn-20231227_lab.xml (EX-101.LAB) — 15KB
- vtgn-20231227_pre.xml (EX-101.PRE) — 11KB
- vtgn20240103_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events   On December 27, 2023, Vistagen Therapeutics, Inc. (the " Company ") issued a press release to announce that the European Patent Office issued a Notice of Intention to Grant a patent related to the use of AV-101, its oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist, for the treatment of neuropathic pain. The patent, once granted, will not expire until at least 2034 and will become part of the Company's global patent portfolio on therapeutic uses and manufacturing techniques for AV-101. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.    
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits .   (d) Exhibits Index   Exhibit No.   Description 99.1   Press Release issued by Vistagen Therapeutics, Inc., dated December 27, 2023. 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)        
Signatures
Signatures   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.     Vistagen Therapeutics, Inc.       Date: January 3, 2024 By: /s/ Shawn K. Singh     Shawn K. Singh Chief Executive Officer